TRAILBLAZER-ALZ Phase II clinical trial
Feb 20, 2023
The Road Ahead for Donanemab: Will the Therapy be the Next Imminent Breakthrough in the Alzheimer’s Disease Treatment Landscape?
Alzheimer’s disease (AD) is becoming a rapidly growing public health concern due to the rise in the world’s aging population. Based on the data obtained from the 2019 Global Burden of Disease (GBD) database, the incidence and prevalence of Alzheimer’s disease and other dementias increased by 147.95 and 160.84%, res...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
